Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:
  • Completed  
  • « Prev · Page 145

NCT ID: NCT00048438 Completed - Clinical trials for Renal Insufficiency, Chronic

Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

NCT ID: NCT00042432 Completed - Clinical trials for Secondary Hyperparathyroidism

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Start date: June 2002
Phase: Phase 2
Study type: Interventional

This study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.

NCT ID: NCT00004285 Completed - Clinical trials for End Stage Renal Disease

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

HEMO
Start date: March 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Evaluate whether hemodialysis providing a 2-pool, variable volume urea kinetic modelling value of 1.05 versus 1.45 reduces mortality and morbidity in patients with end stage renal disease. II. Compare the efficacy of high versus low flux dialyzer membranes.

NCT ID: NCT00000935 Completed - Clinical trials for Kidney Transplantation

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Start date: n/a
Phase: Phase 3
Study type: Interventional

This study is designed to test the clinical and laboratory observations that suggest IVIG given before and after kidney transplant to patients who are sensitized (highly sensitive) to certain transplant antigens could result in reduced sensitization and reduced rates of kidney rejection. Some ESRD patients are highly sensitive to certain transplant antigens (foreign substances that activate the immune system) and must wait for a long time before a well-matched kidney becomes available. Transplant rejection is more likely among highly sensitized patients than in patients who are not highly sensitized. There is no proven method to improve a highly-sensitized patient's chances of receiving and keeping a transplanted kidney.